[go: up one dir, main page]

WO2024097446A3 - Composés théranostiques ciblant la granzyme b - Google Patents

Composés théranostiques ciblant la granzyme b Download PDF

Info

Publication number
WO2024097446A3
WO2024097446A3 PCT/US2023/070835 US2023070835W WO2024097446A3 WO 2024097446 A3 WO2024097446 A3 WO 2024097446A3 US 2023070835 W US2023070835 W US 2023070835W WO 2024097446 A3 WO2024097446 A3 WO 2024097446A3
Authority
WO
WIPO (PCT)
Prior art keywords
granzyme
compounds targeting
targeting
theranostic
theranostic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/070835
Other languages
English (en)
Other versions
WO2024097446A2 (fr
Inventor
Geoffrey Malcolm BILCER
James Kronauge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytosite Biopharma Inc
Original Assignee
Cytosite Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosite Biopharma Inc filed Critical Cytosite Biopharma Inc
Priority to KR1020257004860A priority Critical patent/KR20250040668A/ko
Priority to AU2023372084A priority patent/AU2023372084A1/en
Priority to EP23886770.9A priority patent/EP4561629A2/fr
Priority to JP2025504040A priority patent/JP2025524915A/ja
Priority to CA3262747A priority patent/CA3262747A1/fr
Publication of WO2024097446A2 publication Critical patent/WO2024097446A2/fr
Publication of WO2024097446A3 publication Critical patent/WO2024097446A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des agents théranostiques ciblant la granzyme B à utiliser dans le diagnostic et le traitement du cancer. Des composés thérapeutiques cités à titre d'exemple ciblant la granzyme B peuvent avoir une structure de formule (I) telle que décrite dans la description. L'invention concerne également des méthodes de traitement du cancer comprenant l'administration à un sujet ayant besoin du traitement des composés thérapeutiques ciblant la granzyme B selon l'invention.
PCT/US2023/070835 2022-07-25 2023-07-24 Composés théranostiques ciblant la granzyme b Ceased WO2024097446A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020257004860A KR20250040668A (ko) 2022-07-25 2023-07-24 그랜자임 b를 표적화하는 치료진단 화합물
AU2023372084A AU2023372084A1 (en) 2022-07-25 2023-07-24 Theranostic compounds targeting granzyme b
EP23886770.9A EP4561629A2 (fr) 2022-07-25 2023-07-24 Composés théranostiques ciblant la granzyme b
JP2025504040A JP2025524915A (ja) 2022-07-25 2023-07-24 グランザイムｂを標的とするセラノスティクス化合物
CA3262747A CA3262747A1 (fr) 2022-07-25 2023-07-24 Composés théranostiques ciblant la granzyme b

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263391905P 2022-07-25 2022-07-25
US63/391,905 2022-07-25

Publications (2)

Publication Number Publication Date
WO2024097446A2 WO2024097446A2 (fr) 2024-05-10
WO2024097446A3 true WO2024097446A3 (fr) 2024-07-11

Family

ID=90931706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/070835 Ceased WO2024097446A2 (fr) 2022-07-25 2023-07-24 Composés théranostiques ciblant la granzyme b

Country Status (6)

Country Link
EP (1) EP4561629A2 (fr)
JP (1) JP2025524915A (fr)
KR (1) KR20250040668A (fr)
AU (1) AU2023372084A1 (fr)
CA (1) CA3262747A1 (fr)
WO (1) WO2024097446A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254479A2 (fr) * 2023-06-07 2024-12-12 Cytosite Biopharma Inc. Promédicaments pour composés spécifiques du granzyme b et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019945A1 (en) * 2002-02-04 2006-01-26 Chapman Kevin T Granzyme b inhibitors
WO2021252664A1 (fr) * 2020-06-09 2021-12-16 Cytosite Biopharma Inc. Thérapie et imagerie dirigées par granzyme b
US20220135593A1 (en) * 2019-02-13 2022-05-05 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019945A1 (en) * 2002-02-04 2006-01-26 Chapman Kevin T Granzyme b inhibitors
US20220135593A1 (en) * 2019-02-13 2022-05-05 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
WO2021252664A1 (fr) * 2020-06-09 2021-12-16 Cytosite Biopharma Inc. Thérapie et imagerie dirigées par granzyme b

Also Published As

Publication number Publication date
WO2024097446A2 (fr) 2024-05-10
AU2023372084A1 (en) 2025-01-30
CA3262747A1 (fr) 2024-05-10
EP4561629A2 (fr) 2025-06-04
KR20250040668A (ko) 2025-03-24
JP2025524915A (ja) 2025-08-01

Similar Documents

Publication Publication Date Title
Sandberg et al. Important factors for pain during photodynamic therapy for actinic keratosis.
Dragieva et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
BR9807055A (pt) Composição farmacêutica, uso de um agente fotoquimioterapêutico precursor da protoporfirina junto com um fotossensibilizador de localização de estroma vascular, produto contendo os mesmos, kit para uso em fotoquimioterapia de distúrbios ou anormalidades das superfìcies externa ou interna do corpo, e, processos de tratamento fotoquimioterapêutico de distúrbios ou anormalidades de superfìcies externa ou interna do corpo, e de diagnóstico in vitro de anormalidades ou distúrbios, mediante ensaios de uma amostra de fluidos corporais ou tecidos de um paciente
WO2004004661A3 (fr) Polytherapie a base de composes de boroproline
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CA2464758A1 (fr) Therapie combinant l'utilisation de zd6474 et d'un taxane
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
Balakirski et al. Photodynamic therapy in dermatology: established and new indications
CA2449856A1 (fr) Compositions pharmaceutique et de diagnostic contenant des nanoparticules utiles pour le traitement de tissus et de cellules cibles
MX2024014994A (es) Macrociclos de indazol y su uso
WO2024097446A3 (fr) Composés théranostiques ciblant la granzyme b
IL317168A (en) GCN2 modulator for cancer treatment
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX336390B (es) Formulaciones fotosensibilizadoras mejoradas y su uso.
BRPI0518250A2 (pt) tratamentos anticÂncer
Cappugi et al. New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-aminolevulinic acid
WO2005009217A3 (fr) Diagnostic d'etats precancereux au moyen d'agents pcdgf
CN116726021A (zh) 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途
WO2000006136A3 (fr) METHODE PERMETTANT DE TRAITER LE CANCER CHEZ DES PATIENTS PRESENTANT UNE DEFICIENCE DU SUPPRESSEUR DE TUMEUR p53
CA2458856A1 (fr) Protocoles therapeutiques ameliores
WO2001097678A3 (fr) Imagerie et ciblage de tumeurs au moyen de cellules falciformes
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.
AU2001236529A1 (en) Combination therapy for cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2023372084

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2025504040

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2023372084

Country of ref document: AU

Date of ref document: 20230724

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20257004860

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023886770

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023886770

Country of ref document: EP

Effective date: 20250225

WWP Wipo information: published in national office

Ref document number: 1020257004860

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23886770

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023886770

Country of ref document: EP